# Pneumococcal Vaccine Market

> Pneumococcal Vaccine Market Research Report: Size, Share, Trend Analysis By Types (Conjugate Vaccine, Polysaccharide Vaccine, Recombinant Vaccine), By Age Group (Infants, Children, Adults, Elderly), By Administration Route (Intramuscular, Subcutaneous, Oral), By Indication (Preventive Use, Therapeutic Use) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.87%
- **2024:** $ 7.38 Billion
- **2025:** $ 7.67 Billion
- **2035:** $ 11.21 Billion
- **Key Players:** Pfizer (US), Merck & Co (US), GlaxoSmithKline (GB), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Baxter International (US), Serum Institute of India (IN), Bharat Biotech (IN)

**Report ID:** MRFR/HC/41603-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/pneumococcal-vaccine-market-43269

---

## Market Summary

## **Global Pneumococcal Vaccine Market Overview:**

Pneumococcal Vaccine Market Size was estimated at 7.1 (USD Billion) in 2023. The Pneumococcal Vaccine Market Industry is expected to grow from 7.38 (USD Billion) in 2024 to 11.2 (USD Billion) by 2035. The Pneumococcal Vaccine Market CAGR (growth rate) is expected to be around 3.87% during the forecast period (2025 - 2035).

### **Key Pneumococcal Vaccine Market Trends Highlighted**

The global pneumococcal vaccine market is driven by increasing awareness of respiratory diseases and the benefits of vaccination. The rising incidence of pneumococcal disease is prompting governments and health organizations to promote immunization programs, thereby boosting vaccine adoption. Furthermore, advancements in vaccine technologies and the development of new formulations contribute to the market's dynamic growth. Ongoing research and clinical trials focus on enhancing the efficacy of vaccines, which plays a crucial role in appealing to both healthcare providers and patients.

Opportunities within this market are abundant, especially in emerging economies where healthcare infrastructure is still developing.The expansion of vaccination programs in low- and middle-income countries offers a pathway for greater reach and distribution of pneumococcal vaccines. Increased investment from both public and private sectors in healthcare can further support vaccine accessibility and affordability.

Additionally, integrating pneumococcal vaccination with other routine immunization schedules presents a significant opportunity for market players to enhance their product offerings. Recent trends indicate a shift toward combination vaccines and multi-dose schedules, making immunization more convenient for patients and healthcare providers.

There is also a growing emphasis on preventive healthcare, encouraging individuals to prioritize vaccinations before health issues arise.Increasing digital health initiatives are making it easier for patients to access information on vaccination and schedule appointments. The amalgamation of these factors is shaping the landscape of the pneumococcal vaccine market, highlighting the critical role of collaboration among stakeholders in advancing public health.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Pneumococcal Vaccine Market Drivers**

### **Rising Incidence of Pneumococcal Diseases**

The increasing prevalence of pneumococcal infections worldwide stands as a significant driver for the Global Pneumococcal Vaccine Market Industry. Pneumococcal diseases, which include pneumonia, meningitis, and bacteremia, are caused by the Streptococcus pneumoniae bacteria and are particularly dangerous for vulnerable populations such as infants, the elderly and those with weakened immune systems. The rise in incidence rates can be attributed to several factors, including demographic changes like population aging, urbanization, and the growing prevalence of chronic diseases.

Furthermore, outbreaks of pneumococcal infections in various regions accentuate the urgent need for vaccination. Increased awareness among healthcare professionals regarding pneumococcal diseases and the benefits of vaccination are also key contributors pushing for vaccinations. In several countries, government and health organizations are advocating for wider immunization coverage to curb the impact of these diseases, thus propelling the growth of the Global Pneumococcal Vaccine Market Industry.With rising health concerns and a greater focus on preventive healthcare measures, the market is witnessing substantial growth potential.

Moreover, advancements in vaccine technology, such as the development of newer vaccine formulations that promise higher efficacy, also play a crucial role in stimulating demand. The commitment of various entities, including global health organizations, to eliminate pneumococcal diseases by providing vaccinations forms a crucial aspect of public health policy worldwide.This situation indicates a favorable landscape for sustained market growth as health authorities increasingly invest resources into vaccination programs to combat these diseases effectively.

### **Government Initiatives and Funding**

Government initiatives aimed at enhancing vaccination rates significantly contribute to the growth of the Global Pneumococcal Vaccine Market Industry. Many countries view vaccination as a critical public health strategy to prevent infectious diseases, leading to extensive campaigns and funded programs.

Various governments provide financial support for the purchase and distribution of pneumococcal vaccines, particularly in low- and middle-income countries.This money is important for everybody, especially the vulnerable groups, to get vaccines. The changing government health policies geared towards strengthening immunization should place the global pneumococcal vaccine market at an advantaged position accompanied by steady assistance and coverage.

### **Increased Research and Development Activities**

Innovations through increased research and development are driving the Global Pneumococcal Vaccine Market Industry forward. The ongoing exploration of novel vaccine formulations and delivery methods is pivotal in enhancing immunization rates. Pharmaceutical companies and research institutes are engaged in developing next-generation pneumococcal vaccines that offer improved efficacy and safety profiles.

These efforts are supported by significant investments into research, collaboration between businesses and academia, and clinical trials aimed at optimizing vaccine effectiveness.Consequently, the continuous influx of innovative products serves to attract a larger patient population into vaccination programs, thus paving the way for market growth.

## **Pneumococcal Vaccine Market Segment Insights:**

### **Pneumococcal Vaccine Market Type Insights**

The Global Pneumococcal Vaccine Market is diversely categorized by Type, which significantly impacts its overall dynamics and growth potential. As of 2024, the overall market is set to achieve a valuation of 7.38 USD Billion, with projections suggesting an increase to 11.2 USD Billion by 2035. Within this segmentation, the Conjugate Vaccine demonstrates a substantial market share, valued at 3.0 USD Billion in 2024 and projected to reach 4.5 USD Billion by 2035, thus highlighting its major dominance in the sector.

This vaccine type is pivotal due to its effectiveness in preventing pneumococcal diseases in children and adults, making it a preferred choice in immunization programs across various countries.In comparison, the Polysaccharide Vaccine, valued at 2.5 USD Billion in 2024 and expected to rise to 3.5 USD Billion by 2035, holds a significant position as well. While it is generally used for older populations and those at increased risk, its stability and ease of storage are crucial selling points that contribute to its steady demand.

Meanwhile, the Recombinant Vaccine is valued at 1.88 USD Billion in 2024 and is projected to escalate to 3.2 USD Billion by 2035. Although it is currently the least dominant among the three vaccine types, its importance lies in its innovative approach toward immunization, targeting specific serotypes and potentially offering broader immunity.In terms of market growth, the increasing prevalence of pneumonia and rising awareness about vaccination benefits are key drivers influencing each vaccine type's demand.

Nonetheless, challenges such as vaccine accessibility, manufacturing complexities, and regulatory hurdles remain to be addressed in order to harness the full potential of the Global Pneumococcal Vaccine Market. These dynamics underline the diversification in vaccine types contributing to a comprehensive defense against pneumococcal diseases while also providing various options tailored different population needs.

The segmentation within the Global Pneumococcal Vaccine Market illustrates both challenges and opportunities that actors in the market need to navigate to ensure effective and efficient delivery of these essential vaccines.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Pneumococcal Vaccine Market Age Group Insights**

The Age Group segment plays a critical role in this market, with diverse demographics including Infants, Children, Adults and the Elderly. Infants represent a major portion of the market, as vaccination is crucial for their early protection against pneumococcal diseases, marking them as a focal point in immunization campaigns worldwide. Children also significantly contribute to market dynamics, where ongoing vaccination is essential for ensuring long-term health and immunity.

The Adult demographic is essential due to the increased susceptibility to pneumococcal infections, particularly in high-risk groups, highlighting the importance of updating vaccinations in this population. The Elderly segment dominates the market, given this group's vulnerability to pneumonia and related complications, thus driving demand for effective vaccines.

Overall, the Global Pneumococcal Vaccine Market segmentation showcases a vital interplay between these age groups, reflecting gendered health priorities across various populations while presenting ongoing opportunities for market expansion amid emerging healthcare challenges.

### **Pneumococcal Vaccine Market Administration Route Insights**

The market growth will be driven by increasing awareness about pneumococcal diseases and the importance of vaccination. Within this segment, the most widely adopted routes are Intramuscular and Subcutaneous, which hold significant market share due to their effectiveness and ease of administration in clinical settings.

Notably, Intramuscular injections are preferred in many vaccination programs, becoming a standard practice among healthcare providers, thereby dominating the market.Meanwhile, the Oral administration route continues to gain attention as it offers non-invasive delivery benefits, appealing to patient populations who are averse to needles.

The evolving landscape of vaccination strategies and the need for convenient delivery methods present substantial opportunities within the Global Pneumococcal Vaccine Market. The increasing focus on pediatric immunization further emphasizes these routes, creating a favorable environment for market growth as the awareness surrounding vaccine-preventable diseases rises.

### **Pneumococcal Vaccine Market Indication Insights**

The market is characterized by its two main indications: Preventive Use and Therapeutic Use. Preventive Use dominates the market as it focuses on the vaccination of healthy populations to prevent infections and complications associated with pneumococcus, significantly reducing disease incidence.

Conversely, Therapeutic Use addresses already infected individuals, aiming to manage and mitigate disease progression.The increasing awareness of pneumococcal diseases, alongside rising vaccination drives, serves as a growth driver for both segments. However, challenges such as vaccine accessibility in low-income regions and the emergence of resistant strains pose risks to market expansion.

Despite these challenges, opportunities abound in innovating vaccine formulations and expanding vaccination programs, contributing positively to the Global Pneumococcal Vaccine Market revenue and overall market growth. The overall statistics reflect a steady demand for vaccines, forming a critical component in the fight against pneumococcal diseases.

### **Pneumococcal Vaccine Market Regional Insights**

The Global Pneumococcal Vaccine Market is divided into several regional segments, which highlight key areas of growth and market dynamics. North America, with a market valuation of 2.94 USD Billion in 2024, holds the majority share and is expected to reach 4.47 USD Billion by 2035, demonstrating the region's significant demand for pneumococcal vaccines.

Europe follows, valued at 1.68 USD Billion in 2024 and projected to grow to 2.54 USD Billion in 2035, driven largely by increasing healthcare investments and awareness. The Asia-Pacific (APAC) region is also noteworthy, valued at 1.45 USD Billion in 2024, and is anticipated to grow to 2.19 USD Billion by 2035, owing to expanding healthcare infrastructure and rising vaccination initiatives.

South America and the Middle East Africa (MEA) represent smaller segments valued at 0.73 USD Billion and 0.58 USD Billion in 2024 respectively, and are forecasted to grow to 1.11 USD Billion and 0.89 USD Billion by 2035, reflecting increasing focus on public health initiatives. Collectively, these regional dynamics illustrate the market's diverse landscape as healthcare priorities shift globally, highlighting significant growth opportunities for industry stakeholders within the Global Pneumococcal Vaccine Market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Pneumococcal Va****ccine Market Key Players and Competitive Insights:**

The Global Pneumococcal Vaccine Market presents a dynamic landscape characterized by evolving competitive strategies, innovative product development, and a range of established and emerging players. This market is driven by the increasing awareness of pneumococcal diseases, along with rising healthcare expenditures and governmental initiatives to expand vaccination programs.

Competitive insights reveal that companies are engaging in partnerships, collaborations, and mergers to enhance their market presence. The increasing incidence of pneumococcal diseases, coupled with advancements in vaccine technology, enables companies to differentiate their products through efficacy, safety profiles, and targeted immunization strategies.

The ongoing research and development (RD) efforts are also crucial for companies aiming to optimize their market share and respond to emerging variants of pneumococcus, which implies a strong need for continuous innovation in formulations and delivery methods.Valneva has carved out a significant position within the Global Pneumococcal Vaccine Market through its focus on developing unique vaccines with promising profiles.

The company's strengths lie in its robust RD capabilities, which aid in the creation of effective pneumococcal vaccine candidates. Valneva emphasizes a patient-centric approach, ensuring that the vaccines developed not only meet regulatory requirements but also are designed to be widely accepted in diverse populations. The company’s strategic partnerships with global health organizations facilitate its entry into emerging markets, enhancing its footprint.

Additionally, Valneva’s commitment to sustainability and production scalability positions it favorably in the competitive landscape, allowing for responsive manufacturing to meet growing demand.Merck is another key player in the Global Pneumococcal Vaccine Market, recognized for its longstanding expertise in vaccine development and production.

The firm possesses a well-established reputation for quality and innovation, contributing significantly to its market strength. Merck's diverse product portfolio is bolstered by its advanced technological prowess, enabling the creation of vaccines that offer broad protection against pneumococcal strains.

Furthermore, the company's commitment to global health initiatives aligns with increasing immunization efforts worldwide, thereby enhancing its visibility and influence. Merck continuously invests in clinical trials and RD to ensure its vaccines not only comply with the highest safety and efficacy standards but also adapt to the ever-changing epidemiological landscape of pneumococcal diseases.

### **Key Companies in the Pneumococcal Vaccine Market Include:**

- Valneva
- Merck
- Pfizer
- Baxter International
- GlaxoSmithKline
- Mitsubishi Tanabe Pharma
- Zydus Cadila
- Boehringer Ingelheim
- Serum Institute of India
- Covenant Health
- Sanofi
- **[Novartis](https://www.novartis.com/about/products)**
- AstraZeneca
- Indian Immunologicals

## Pneumococcal Vaccine Market Industry Developments

- **Q2 2024: Pfizer Receives FDA Approval for PENBRAYA™, the First and Only Vaccine for the Prevention of Meningococcal Groups A, B, C, W, and Y** Pfizer announced that the U.S. FDA approved PENBRAYA™, a new vaccine that includes protection against pneumococcal disease, marking a significant regulatory milestone for the company’s vaccine portfolio.
- **Q2 2024: GSK receives European Commission approval for Arexvy, the first RSV vaccine for older adults** GSK received European Commission approval for Arexvy, which, while primarily an RSV vaccine, is part of GSK’s broader adult vaccine strategy that includes pneumococcal vaccine development and launches.
- **Q2 2024: Merck Announces U.S. FDA Approval of VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children** Merck received FDA approval for VAXNEUVANCE® for use in infants and children, expanding the label of its pneumococcal conjugate vaccine to a younger population.
- **Q2 2024: SK Bioscience to build new vaccine manufacturing plant in South Korea** SK Bioscience announced plans to construct a new vaccine manufacturing facility in South Korea, which will include production lines for pneumococcal vaccines to meet growing global demand.
- **Q3 2024: Pfizer and BioNTech Announce Expansion of Vaccine Manufacturing Collaboration** Pfizer and BioNTech expanded their manufacturing partnership to include additional capacity for pneumococcal conjugate vaccines, aiming to increase global supply.
- **Q3 2024: GSK and Walvax Announce Strategic Partnership to Co-Develop Next-Generation Pneumococcal Vaccines** GSK and Walvax Biotechnology announced a strategic partnership to co-develop and commercialize next-generation pneumococcal conjugate vaccines for global markets.
- **Q3 2024: Serum Institute of India launches new pneumococcal vaccine for African markets** Serum Institute of India launched a new, affordable pneumococcal conjugate vaccine targeting African countries, aiming to increase access and coverage in low-income regions.
- **Q4 2024: Merck Announces $500 Million Investment in New Vaccine Manufacturing Facility** Merck announced a $500 million investment to build a new vaccine manufacturing facility in the United States, with a focus on expanding production of pneumococcal and other pediatric vaccines.
- **Q4 2024: China’s Walvax gets regulatory approval for 13-valent pneumococcal conjugate vaccine** Walvax Biotechnology received regulatory approval in China for its 13-valent pneumococcal conjugate vaccine, enabling domestic production and distribution.
- **Q1 2025: Pfizer Announces $1 Billion Investment in Global Vaccine R&D Center** Pfizer announced a $1 billion investment to establish a new global vaccine R&D center, with a focus on developing next-generation pneumococcal and other infectious disease vaccines.
- **Q2 2025: BioNTech to Acquire German Vaccine Startup Specializing in Pneumococcal Technology** BioNTech announced the acquisition of a German biotech startup specializing in pneumococcal vaccine technology, aiming to strengthen its pipeline in bacterial vaccines.
- **Q2 2025: GSK secures $200 million contract to supply pneumococcal vaccines to UNICEF** GSK secured a $200 million contract to supply pneumococcal conjugate vaccines to UNICEF for use in global childhood immunization programs.

## **Pneumococcal Vaccine Market Segmentation Insights**

### **Pneumococcal Vaccine Market Type Outlook**

- Conjugate Vaccine
- Polysaccharide Vaccine
- Recombinant Vaccine

### **Pneumococcal Vaccine Market Age Group Outlook**

- Infants
- Children
- Adults
- Elderly

### **Pneumococcal Vaccine Market Administration Route Outlook**

- Intramuscular
- [Subcutaneous](../../../reports/subcutaneous-neurofibroma-market-39397)
- Oral

### **Pneumococcal Vaccine Market Indication Outlook**

- Preventive Use
- Therapeutic Use

### **Pneumococcal Vaccine Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Government Initiatives and Funding

Government initiatives aimed at combating infectious diseases are significantly influencing the Pneumococcal Vaccine Market. Many countries have implemented national immunization programs that include pneumococcal vaccines, often supported by substantial funding. For instance, various health departments allocate budgets specifically for vaccine procurement and distribution, which enhances accessibility for populations at risk. These initiatives not only promote vaccination but also raise public awareness about the importance of immunization. As governments continue to recognize the economic and health benefits of preventing pneumococcal diseases, the financial backing for vaccine programs is expected to increase, further propelling the Pneumococcal Vaccine Market.

### Increased Public Awareness and Education

Increased public awareness and education regarding pneumococcal diseases are pivotal drivers of the Pneumococcal Vaccine Market. Campaigns aimed at educating the public about the risks associated with pneumococcal infections and the benefits of vaccination have gained traction. Health organizations and non-profits are actively disseminating information through various channels, including social media, community outreach, and healthcare provider engagement. This heightened awareness is leading to greater acceptance of pneumococcal vaccines among the general population. As more individuals recognize the importance of preventive healthcare, the demand for pneumococcal vaccines is expected to rise, positively impacting the Pneumococcal Vaccine Market.

### Rising Incidence of Pneumococcal Diseases

The Pneumococcal Vaccine Market is experiencing growth due to the rising incidence of pneumococcal diseases, which include pneumonia, meningitis, and sepsis. These diseases are particularly prevalent among vulnerable populations, such as children and the elderly. According to health statistics, pneumonia caused by Streptococcus pneumoniae remains a leading cause of morbidity and mortality worldwide. The increasing awareness of these diseases has led to heightened demand for pneumococcal vaccines, as healthcare providers and governments prioritize vaccination programs. This trend is likely to continue, as the burden of pneumococcal diseases prompts further investment in vaccine development and distribution, thereby driving the Pneumococcal Vaccine Market forward.

### Aging Population and Chronic Health Conditions

The aging population, coupled with an increase in chronic health conditions, is a significant factor influencing the Pneumococcal Vaccine Market. Older adults are at a higher risk for pneumococcal diseases due to weakened immune systems and the prevalence of comorbidities such as diabetes and heart disease. As the global demographic shifts towards an older population, the demand for pneumococcal vaccines is likely to escalate. Healthcare systems are increasingly focusing on preventive measures to reduce the burden of disease among older adults. This trend suggests that the Pneumococcal Vaccine Market will continue to expand as vaccination becomes a critical component of healthcare strategies for aging populations.

### Technological Innovations in Vaccine Production

Technological innovations in vaccine production are transforming the Pneumococcal Vaccine Market. Advances in biotechnology, such as recombinant DNA technology and mRNA vaccine platforms, have led to the development of more effective and safer pneumococcal vaccines. These innovations enable faster production times and improved efficacy, which are crucial in addressing the evolving strains of pneumococcal bacteria. The introduction of new vaccine formulations, including [conjugate vaccines](https://www.marketresearchfuture.com/reports/conjugate-vaccine-market-4387), has expanded the options available to healthcare providers. As these technologies continue to evolve, they are likely to enhance the overall effectiveness of vaccination programs, thereby stimulating growth in the Pneumococcal Vaccine Market.

## Future Outlook

The Pneumococcal Vaccine Market is projected to grow at a 3.87% CAGR from 2025 to 2035, driven by increasing vaccination awareness, technological advancements, and rising healthcare expenditures.

**New opportunities:**

- Expansion of telehealth services for vaccine consultations Development of combination vaccines to enhance immunization rates Strategic partnerships with healthcare providers for outreach programs

By 2035, the market is expected to be robust, reflecting sustained growth and innovation.

## Segment Insights

### By Type: Conjugate Vaccine (Largest) vs. Polysaccharide Vaccine (Fastest-Growing)

The Pneumococcal Vaccine Market is characterized by a diverse range of products, with the Conjugate Vaccine segment holding the largest market share. Conjugate vaccines are essential due to their effectiveness in preventing severe pneumonia and invasive disease, particularly in children. On the other hand, the Polysaccharide Vaccine segment, while smaller in share, is experiencing rapid growth driven by increasing awareness and rising incidence of pneumococcal diseases among adults and elderly populations. Furthermore, these vaccines are crucial in areas with limited access to healthcare resources, which enhances their appeal in emerging markets.

Emerging trends indicate that the Recombinant Vaccine segment is also gaining traction due to ongoing research and development efforts. Factors such as the rising prevalence of pneumococcal diseases, the need for improved vaccine options, and government initiatives towards vaccination programs are contributing to the growth in this segment. Moreover, innovations in vaccine technology, including tailored vaccines, are attracting attention and investment in the PCV market. As awareness of the importance of pneumococcal vaccines continues to rise, the segments are expected to expand and evolve in the coming years.

Conjugate Vaccine (Dominant) vs. Recombinant Vaccine (Emerging)

The Conjugate Vaccine segment is the dominant player in the Pneumococcal Vaccine Market, widely recognized for its effectiveness in preventing disease in young children and high-risk populations. It is distinguished by its ability to elicit a robust immune response, contributing to herd immunity. Conversely, the Recombinant Vaccine segment is emerging as a promising alternative, characterized by its potential for targeted action against specific pneumococcal strains. Advances in biotechnology have accelerated the development of [recombinant vaccines](https://www.marketresearchfuture.com/reports/recombinant-vaccines-market-6130), making them a compelling option as they promise to reduce adverse reactions and enhance effectiveness. As healthcare providers explore varied strategies to combat pneumococcal diseases, both segments are poised to play crucial roles in public health efforts.

### By Age Group: Infants (Largest) vs. Elderly (Fastest-Growing)

The Pneumococcal Vaccine Market exhibits a significant distribution of market share across various age groups, with infants holding the largest share due to the established vaccination schedules and guidelines. Children's share contributes notably, while the elderly segment, although smaller in current distribution, is gaining traction as awareness of pneumococcal disease's impact grows. The PCV market dynamics are evolving, influenced by various factors affecting each age group's healthcare deliverables.

Growth trends for the Pneumococcal Vaccine Market across age segments reveal a promising trajectory, especially for the elderly, who are experiencing the fastest growth. Increased healthcare access, advocacy for immunization amongst older populations, and rising incidences of pneumococcal disease in this age group are significant drivers. Meanwhile, the stable market share from infants showcases the continued importance of early immunization and its integration into standard pediatric care practices.

Infants (Dominant) vs. Adults (Emerging)

Infants constitute the dominant segment in the Pneumococcal Vaccine Market, driven by proactive immunization schedules designed to protect against severe respiratory infections early in life. Healthcare institutions emphasize the importance of this vaccination, resulting in high coverage rates and consistent public health messaging. Conversely, the adult segment is emerging, propelled by rising awareness of pneumococcal disease risks that adults face, especially those with comorbidities. Factors such as healthcare campaigns targeting adults and increased recommendations from medical professionals contribute to the growth potential of this segment, although it currently trails behind infant vaccinations in overall market share.

### By Administration Route: Intramuscular (Largest) vs. Subcutaneous (Fastest-Growing)

In the Pneumococcal Vaccine Market, the administration route segment showcases a clear distribution of preferences among healthcare providers and patients. The dominant administration route is intramuscular, recognized for its high efficacy and widespread acceptance within clinical settings. Subcutaneous administration, while having a smaller share, is rapidly gaining traction due to its ease of delivery and patient comfort, particularly in pediatric populations. Oral vaccines, though present, are less common in this specific market segment.

Administration Route: Intramuscular (Dominant) vs. Subcutaneous (Emerging)

Intramuscular administration remains the dominant route for pneumococcal vaccines, as it allows for deeper penetration into muscle tissue, facilitating better absorption and immune response. This technique is often preferred in hospital and clinical environments due to its established efficacy and safety profile. Conversely, subcutaneous administration is emerging as a competitive alternative, especially for its convenience, with healthcare providers recognizing its potential for outpatient settings. The switch to subcutaneous can enhance patient compliance, particularly among children and those requiring multiple doses, as it minimizes the discomfort associated with injections.

### By Indication: Preventive Use (Largest) vs. Therapeutic Use (Fastest-Growing)

The Pneumococcal Vaccine Market is primarily divided into preventive and therapeutic uses, with preventive use making up the largest share. This segment has been dominant due to its widespread recommendation for children, the elderly, and at-risk populations, thereby ensuring high uptake rates among these groups. In contrast, the therapeutic use of pneumococcal vaccines is gradually increasing and is expected to capture a growing portion of the market, fueled by advancements in medical treatments and heightened awareness of pneumococcal diseases.

Prevention (Dominant) vs. Therapy (Emerging)

In the Pneumococcal Vaccine Market, preventive use is characterized by products that protect individuals before exposure to pathogens. This segment benefits from strong public health initiatives and immunization programs aimed at reducing incidence rates among vulnerable populations. Meanwhile, therapeutic use, although emerging, is gaining prominence as treatment options evolve. It appeals mainly to patients affected by pneumococcal infections, with healthcare providers increasingly recognizing the importance of vaccination in managing disease. The growing incidence of antibiotic-resistant strains is particularly driving interest in therapeutic vaccines, marking a significant development in both preventive and therapeutic approaches.

## Regional Market Share Analysis

The Global Pneumococcal Vaccine Market is divided into several regional segments, which highlight key areas of growth and market dynamics. North America, with a market valuation of 2.94 USD Billion in 2024, holds the majority share and is expected to reach 4.47 USD Billion by 2035, demonstrating the region's significant demand for pneumococcal vaccines.

Europe follows, valued at 1.68 USD Billion in 2024 and projected to grow to 2.54 USD Billion in 2035, driven largely by increasing healthcare investments and awareness. The Asia-Pacific (APAC) region is also noteworthy, valued at 1.45 USD Billion in 2024, and is anticipated to grow to 2.19 USD Billion by 2035, owing to expanding healthcare infrastructure and rising vaccination initiatives.

South America and the Middle East Africa (MEA) represent smaller segments valued at 0.73 USD Billion and 0.58 USD Billion in 2024 respectively, and are forecasted to grow to 1.11 USD Billion and 0.89 USD Billion by 2035, reflecting increasing focus on public health initiatives. Collectively, these regional dynamics illustrate the market's diverse landscape as healthcare priorities shift globally, highlighting significant growth opportunities for industry stakeholders within the Global Pneumococcal Vaccine Market.

## Competitive Benchmarking

The Global Pneumococcal Vaccine Market presents a dynamic landscape characterized by evolving competitive strategies, innovative product development, and a range of established and emerging players. This market is driven by the increasing awareness of pneumococcal diseases, along with rising healthcare expenditures and governmental initiatives to expand vaccination programs. Competitive insights reveal that companies are engaging in partnerships, collaborations, and mergers to enhance their market presence. The increasing incidence of pneumococcal diseases, coupled with advancements in vaccine technology, enables companies to differentiate their products through efficacy, safety profiles, and targeted immunization strategies. The ongoing research and development (RD) efforts are also crucial for companies aiming to optimize their market share and respond to emerging variants of pneumococcus, which implies a strong need for continuous innovation in formulations and delivery methods.Valneva has carved out a significant position within the Global Pneumococcal Vaccine Market through its focus on developing unique vaccines with promising profiles. The company's strengths lie in its robust RD capabilities, which aid in the creation of effective pneumococcal vaccine candidates. Valneva emphasizes a patient-centric approach, ensuring that the vaccines developed not only meet regulatory requirements but also are designed to be widely accepted in diverse populations. The company’s strategic partnerships with global health organizations facilitate its entry into emerging markets, enhancing its footprint. Additionally, Valneva’s commitment to sustainability and production scalability positions it favorably in the competitive landscape, allowing for responsive manufacturing to meet growing demand.Merck is another key player in the Global Pneumococcal Vaccine Market, recognized for its longstanding expertise in vaccine development and production. The firm possesses a well-established reputation for quality and innovation, contributing significantly to its market strength. Merck's diverse product portfolio is bolstered by its advanced technological prowess, enabling the creation of vaccines that offer broad protection against pneumococcal strains. Furthermore, the company's commitment to global health initiatives aligns with increasing immunization efforts worldwide, thereby enhancing its visibility and influence. Merck continuously invests in clinical trials and RD to ensure its vaccines not only comply with the highest safety and efficacy standards but also adapt to the ever-changing epidemiological landscape of pneumococcal diseases.

## Recent News & Developments

- **Q2 2024: Pfizer Receives FDA Approval for PENBRAYA™, the First and Only Vaccine for the Prevention of Meningococcal Groups A, B, C, W, and Y** Pfizer announced that the U.S. FDA approved PENBRAYA™, a new vaccine that includes protection against pneumococcal disease, marking a significant regulatory milestone for the company’s vaccine portfolio.
- **Q2 2024: GSK receives European Commission approval for Arexvy, the first RSV vaccine for older adults** GSK received European Commission approval for Arexvy, which, while primarily an RSV vaccine, is part of GSK’s broader adult vaccine strategy that includes pneumococcal vaccine development and launches.
- **Q2 2024: Merck Announces U.S. FDA Approval of VAXNEUVANCE® (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children** Merck received FDA approval for VAXNEUVANCE® for use in infants and children, expanding the label of its pneumococcal conjugate vaccine to a younger population.
- **Q2 2024: SK Bioscience to build new vaccine manufacturing plant in South Korea** SK Bioscience announced plans to construct a new vaccine manufacturing facility in South Korea, which will include production lines for pneumococcal vaccines to meet growing global demand.
- **Q3 2024: Pfizer and BioNTech Announce Expansion of Vaccine Manufacturing Collaboration** Pfizer and BioNTech expanded their manufacturing partnership to include additional capacity for pneumococcal conjugate vaccines, aiming to increase global supply.
- **Q3 2024: GSK and Walvax Announce Strategic Partnership to Co-Develop Next-Generation Pneumococcal Vaccines** GSK and Walvax Biotechnology announced a strategic partnership to co-develop and commercialize next-generation pneumococcal conjugate vaccines for global markets.
- **Q3 2024: Serum Institute of India launches new pneumococcal vaccine for African markets** Serum Institute of India launched a new, affordable pneumococcal conjugate vaccine targeting African countries, aiming to increase access and coverage in low-income regions.
- **Q4 2024: Merck Announces $500 Million Investment in New Vaccine Manufacturing Facility** Merck announced a $500 million investment to build a new vaccine manufacturing facility in the United States, with a focus on expanding production of pneumococcal and other pediatric vaccines.
- **Q4 2024: China’s Walvax gets regulatory approval for 13-valent pneumococcal conjugate vaccine** Walvax Biotechnology received regulatory approval in China for its 13-valent pneumococcal conjugate vaccine, enabling domestic production and distribution.
- **Q1 2025: Pfizer Announces $1 Billion Investment in Global Vaccine R&D Center** Pfizer announced a $1 billion investment to establish a new global vaccine R&D center, with a focus on developing next-generation pneumococcal and other infectious disease vaccines.
- **Q2 2025: BioNTech to Acquire German Vaccine Startup Specializing in Pneumococcal Technology** BioNTech announced the acquisition of a German biotech startup specializing in pneumococcal vaccine technology, aiming to strengthen its pipeline in bacterial vaccines.
- **Q2 2025: GSK secures $200 million contract to supply pneumococcal vaccines to UNICEF** GSK secured a $200 million contract to supply pneumococcal conjugate vaccines to UNICEF for use in global childhood immunization programs.

## Report Scope

| MARKET SIZE 2024 | 7.38(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 7.666(USD Billion) |
| MARKET SIZE 2035 | 11.21(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.87% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Pfizer (US), Merck & Co (US), GlaxoSmithKline (GB), Sanofi (FR), AstraZeneca (GB), Novartis (CH), Baxter International (US), Serum Institute of India (IN), Bharat Biotech (IN) |
| Segments Covered | Types, Age Group, Administration Route, Indication, Regional |
| Key Market Opportunities | Advancements in mRNA technology may enhance efficacy and accessibility in the Pneumococcal Vaccine Market. |
| Key Market Dynamics | Rising demand for pneumococcal vaccines driven by regulatory changes and increasing awareness of respiratory diseases. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Pneumococcal Vaccine Market?**
A: The Pneumococcal Vaccine Market was valued at 7.38 USD Billion in 2024.

**Q: What is the projected market size for the Pneumococcal Vaccine Market by 2035?**
A: The market is projected to reach 11.21 USD Billion by 2035.

**Q: What is the expected CAGR for the Pneumococcal Vaccine Market from 2025 to 2035?**
A: The expected CAGR for the Pneumococcal Vaccine Market during the forecast period 2025 - 2035 is 3.87%.

**Q: Which companies are the key players in the Pneumococcal Vaccine Market?**
A: Key players include Pfizer, Merck & Co, GlaxoSmithKline, Sanofi, AstraZeneca, Novartis, Baxter International, Serum Institute of India, and Bharat Biotech.

**Q: What are the market segments for Pneumococcal Vaccines based on type?**
A: The market segments include Conjugate Vaccine, Polysaccharide Vaccine, and Recombinant Vaccine, with valuations of 3.5, 2.0, and 1.88 USD Billion respectively in 2024.

**Q: How does the Pneumococcal Vaccine Market perform across different age groups?**
A: In 2024, the market performance across age groups was 1.5 USD Billion for infants, 1.8 USD Billion for children, 2.5 USD Billion for adults, and 1.58 USD Billion for the elderly.

**Q: What are the administration routes for Pneumococcal Vaccines?**
A: The administration routes include Intramuscular, Subcutaneous, and Oral, with valuations of 3.0, 2.0, and 2.38 USD Billion respectively in 2024.

**Q: What are the indications for Pneumococcal Vaccines in the market?**
A: The indications include Preventive Use, valued at 4.42 USD Billion, and Therapeutic Use, valued at 2.96 USD Billion in 2024.

**Q: What is the growth potential for the Pneumococcal Vaccine Market?**
A: The market appears to have substantial growth potential, with a projected increase to 11.21 USD Billion by 2035.

**Q: How do the key players influence the Pneumococcal Vaccine Market?**
A: Key players like Pfizer and Merck & Co likely influence market dynamics through innovation and competitive strategies.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/pneumococcal-vaccine-market-43269*